News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

79% Of Americans Drink 2+ Cups Of Coffee Per Day, Survey Finds

Finance News

America runs on coffee with the average US adult consuming more than one cup per day, a number which is increasing with more people working from home. After crunching numbers sourced from Statista, the data analysts at Safe Betting Sites have found that 79 percent of coffee drinkers in the US are drinking two or more cups per day when they are at home on a weekday. Meanwhile, 62 percent of coffee drinkers are consuming a to-go coffee at least once per week with 20 percent drinking a to-go coffee every day. Drip coffee remains America’s preferred way to enjoy a cup of joe with 36 percent of respondents saying it was their favorite. More than half of US adults (51 percent) also agreed with the statement that “coffee is a pure pleasure to me”. 79% Of American Coffee Drinkers Are Consuming 2+ Cups Of Coffee Per Day Since the start of the COVID-19 pandemic, more Americans have been working from home, and for some, that means drinking more coffee. According to a recent survey by Statista, 79 percent of American coffee drinkers are consuming at least two cups per day when at home on a weekday. Only 21 percent of respondents said that they drank just one cup of coffee or fewer when at home. The survey, which was sourced from Statista, analyzed the habits of 831 daily coffee drinkers in the US aged 18-74. By comparison, 31 percent of respondents drank 4-6 cups of coffee per day while 20 percent consumed 3 cups and 27 percent consumed 2 cups of coffee per day. 62% Of Coffee Drinkers Buy A To-Go Coffee At Least 1x Per Week Coffee lovers aren’t just drinking coffee when they are at home either. In fact, 44 percent of Americans are drinking a to-go coffee more than once per week. That compares to 21 percent that said they drank one to-go coffee per week and 38 percent that said they drank a to-go coffee less often or even never. Overall, 20 percent of coffee drinkers said that they drank at least one to-go coffee every day. Drip Coffee (36%) Is America’s Favorite Way To Drink Coffee The survey also asked Americans to rate their favorite way to brew their coffee. Good old-fashioned drip coffee remains America’s preferred way to drink coffee with 36 percent of respondents saying it was their favorite. Cappuccino (11 percent), Iced Coffee (10 percent), and Instant Coffee (nine percent) were among the next on the list of America’s favorite way to drink coffee. Drip Coffee — 36% Cappuccino — 11% Iced Coffee — 10% Instant Coffee — 9% 74% Of Americans Drink Coffee Every Day Of course, this isn’t the first time that Statista polled Americans on their coffee drinking habits. The findings confirm another Statista study from the summer. Back in June 2022, Statista asked 1,592 Americans how often they drank coffee. A whopping 73.9 percent of respondents answered “every day” compared to 17.5 percent that responded “most days”. Meanwhile, only 8.5 percent of respondents were occasional coffee drinkers who responded “sometimes”. Coffee Is 2nd-Most Popular Drink After Bottled Water Coffee is still America’s drink of choice, according to a Statista poll that surveyed over 7,500 US adults from October 2021 to September 2022. In fact, only bottled water is consumed by more Americans as their drink of choice (63 percent). Trailing coffee, soft drinks (56 percent), juice (50 percent) and tea (48 percent) were also among the most common beverages consumed by US adults. When it comes to alcohol, beer (25 percent) edged out wine (24 percent) for the most popular alcoholic beverage in the US. Here are the full results from the poll below. Bottled Water — 63% Coffee — 57% Soft Drinks — 56% Juice — 50% Tea — 48% Energy Drinks — 27% Beer — 25% Wine — 24% For full survey data, visit: https://www.safebettingsites.com/2023/01/19/79-of-americans-drink-2-cups-of-coffee-per-day-survey-finds/ Contact Details Finance News Alex Brown alex@financenews.com

January 23, 2023 05:40 PM Eastern Standard Time

Article thumbnail Digital Asset Direct

BiVictriX Therapeutics makes 'fundamental step forward'

BlueRush Inc.

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 22, 2023 07:55 AM Eastern Standard Time

Video
Article thumbnail News Release

Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women

Agile Therapeutics, Inc.

By Johnny Rice, Benzinga Al Altomari, Chairman and CEO of Agile Therapeutics Inc (NASDAQ: AGRX), was recently interviewed by Benzinga. Agile Therapeutics says it is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Its products and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. The company’s flagship product is Twirla® (levonorgestrel and ethinyl estradiol), a non-daily prescription contraceptive utilizing a transdermal system. Twirla is based on proprietary transdermal patch technology, called Skinfusion®, designed to allow drug delivery through the skin. Watch the full interview here: Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Matt Riley - Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com/

January 20, 2023 08:45 AM Eastern Standard Time

Video
Article thumbnail News Release

Kinspire Raises $3.6M to Reimagine Pediatric Occupational Therapy By Including Parents for Better Outcomes

Kinspire

Denver, CO — January 20, 2022 – Kinspire, the leading pediatric occupational therapy platform designed to pair expert therapists with parents, co-founded by Lily Baiser and Robert Seigel, today announced it has closed $3.6 million in seed funding. The round was co-led by Corazon Capital and Looking Glass Capital, with participation from Difference Partners, Great Oaks VC, Service Provider Capital, The Fund, Copper Wire Ventures, and Bradley Tusk. Launched in 2020, Kinspire provides a family-centered and value-based care model for pediatric occupational therapy to families of children with developmental delays and disabilities. Roughly 1 in 6 children in America are diagnosed with developmental delays or disabilities and can greatly benefit from services such as occupational therapy. However, long waitlists for evaluations, high costs of services, and inconvenient provider distribution produce accessibility and affordability constraints. Moreover, studies have repeatedly demonstrated that involving parents in their child's occupational therapy leads to better outcomes and faster progress. Despite this, traditional OT approaches do not always fully incorporate parent involvement. These constraints often lead to significant delays or a complete lack in children receiving critical pediatric therapeutic services, such as occupational therapy. “The current model for delivering development support services to children fails far too many kids. We have invested in Kinspire to accelerate its mission to make occupational therapy more accessible, affordable, and effective,” said Sam Yagan, Co-Founder & Managing Partner of Corazon Capital. In response, Kinspire has pioneered an entirely new approach to pediatric occupational therapy designed to empower parents to support their child's therapy at home and become an active member of the treatment team. This family-centered care model is in alignment with Harvard’s Center for the Developing Child and Early Intervention Programs. The Spiral Foundation conducted a 12-week study on the use of the Kinspire app for occupational therapy in pediatrics. Over 70% of parents reported that Kinspire made it easier to select activities for home therapy, and the study concluded that the app has preliminary potential as a tool for augmenting clinic-based services. Guided by Kinspire’s expert occupational therapists, children receive high-quality care and parents learn the skills, strategies, and techniques needed to help their child reach their full potential and reduce their own stress. By focusing on the unique needs and goals of each child, Kinspire provides the most effective and efficient care possible for the entire family unit. "As a parent who has personally gone through OT with my child, I have seen firsthand the benefits of being an active participant in the therapy process. That's why we have made it a cornerstone of our pediatric OT platform at Kinspire. This funding allows us to create high levels of collaboration between therapists and parents for better outcomes and faster progress for every child.” said Robert Seigel, CEO & Co-Founder of Kinspire. Unlike traditional occupational therapy, families who use Kinspire pay a monthly membership fee for Kinspire’s multimodal connection to their therapist. Families receive around-the-clock support from their Kinspire therapist with unlimited messaging services, a live 1:1 monthly session, daily parent education, and ongoing access to Kinspire’s mobile app and video library to monitor and measure progress. ABOUT KINSPIRE: Kinspire is the leading family-centered and value-based care model for pediatric occupational therapy on a mission to deliver the highest quality developmental care with better outcomes in less time. Currently providing services in Florida, California, Colorado, and Texas. Kinspire accepts FSA and HSA and is actively working to expand its list of insurance coverage providers to ensure its services are accessible to more children and families. For more information about Kinspire, please visit www.kinspirehealth.com Contact Details Christina Goldstein cgoldstein@tuskholdings.com Jennifer Mingucci Jennifer@KinspireApp.com Company Website https://www.kinspirehealth.com

January 20, 2023 08:15 AM Eastern Standard Time

Article thumbnail News Release

Medica Group eyeing up "significant opportunity"

Medica Group PLC

Medica Group PLC (LSE:MGP) chief executive Dr Stuart Quin speaks to Proactive's Thomas Warner following the release of a 2022 trading update. He reveals more information about what he calls a "significant opportunity' for the Medica Group as it heads into another new year, and discusses where he believes the bulk of its growth will come from. Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

January 20, 2023 07:05 AM Eastern Standard Time

Video
Article thumbnail News Release

Prescriptions Generated Three Times More Frequently on POC Mediums: Doceree 2022 Annual Report

Doceree

Point-of-Care (POC) channels have changed the dynamics of how life sciences brands interact with healthcare professionals (HCPs) which has led to script generation to become three times on POC than on other online mediums, Doceree has revealed in its annual report – Doceree 360 (2022 Edition). Doceree, a global platform building unprecedented solutions for HCP programmatic messaging with proprietary data tools, today released its annual report, compiled post analysis of more than 250 POC campaigns run on its platform over the last year. To drive prescriptions, it is crucial for life sciences brands to target HCPs while they tend to their patients, which is only on point-of-care channels, concludes the report. Doceree has pioneered initiatives to evolve the POC ecosystem with insightful learnings for life sciences brand marketers and platforms. A few months prior to the report launch, the company’s Founder and CEO Harshit Jain, MD launched a book on the subject with the goal of preparing marketers and point-of-care platforms for the next way to effectively reach and engage clinicians through online platforms. “The POC landscape is in its nascent stage and is evolving at a fast pace,” Jain said. “There is apparently a lack of standardization owing to limited availability of data points and metrics at this stage. “We are attempting to fill this gap by diving into the multiple POC campaigns we have executed on our platform in the past year to deduce some insightful learnings for marketers to take cognisance of,” he continued. “It will empower them to embrace data-driven strategies and personalize HCP communications with a deep understanding of online behavior patterns of providers based on real-time campaigns.” The other key findings in the report are: HCPs spend an average of six hours out of an average 11-hour workday on EHR Script lift is 32% higher in trigger-based messaging Cost per HCP is 17% less on POC than on other mediums Doceree gauged more than 21 million impressions served to more than 600,000 HCPs on its over 70-partner POC channels. Campaigns of around 100 advertisers - comprising consumer healthcare and medical devices companies, life sciences brands, hospitals, and diagnostics - run on a blend of POC channels, consisting of EHR, eRx, telemedicine, EHR apps, were taken into account. Brand campaigns for more than 190 specialties, including Primary Care, Cardiology, Oncology, Hematology, Nephrology, Gynaecology and Pulmonology, were studied as part of the research for the report findings. View the complete report by visiting: https://doceree.com/in/reports/doceree-360-2022-edition/ About Doceree Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs and transparent marketing campaign metrics at scale. To learn more, visit doceree.com. Contact Details Kite Hill PR +91 70420 89805 doceree@kitehillpr.com Company Website https://doceree.com/us/

January 19, 2023 11:20 AM Eastern Standard Time

Image
Article thumbnail News Release

Oliver Inc. Acquires Tap Packaging + Design

Oliver Inc.

Oliver Inc. (“Oliver”) is pleased to announce that it has acquired Tap Packaging + Design. Tap Packaging is a leading manufacturer of custom folding cartons, serving customers in food and beverage, beauty, confection, health and wellness, and consumer goods markets. Based in Cleveland, Ohio, Tap Packaging will continue delivering design-forward packaging solutions from its current location. This partnership will enable Oliver to expand its product offerings and strengthen its position as the nation’s largest independent specialty packaging supplier. “We are thrilled to welcome the Tap team to the Oliver family,” said Dan Rodenbush, President/CEO of Oliver Inc. "Their diverse range of capabilities will allow us to expand our product offerings and enhance our overall service for our customers.” “Oliver and Tap Packaging share similar core values, and both companies have a passion for providing an exceptional customer experience,” added David Chilcote, Chairman of Tap Packaging. “Partnering with Oliver increases our capacity, provides redundancy, and allows us to better leverage our combined scale to offer enhanced solutions for our customers.” Oliver has made significant investments in modern equipment, facilities, and people since 2016. The Tap Packaging transaction will represent Oliver’s fifth strategic acquisition and aligns with the company’s vision to build a leading provider of innovative, specialty packaging solutions. The transaction closed on January 18, 2023. To learn more about Oliver, please visit www.oliverinc.com. About Oliver Oliver Inc. is a leading provider of highly customized, quick-turnaround, specialty packaging solutions. Known for its white-glove approach to customer service, the company provides a turnkey platform from design to fulfillment, simplifying complex requirements with consistent on-time, on-budget, ultra-high-quality products and services. About Tap Packaging + Design Since 1906, Tap Packaging + Design has been committed to enhancing their customers’ image by providing high-quality packaging and presentation products. The company’s success can be attributed to the creative craftsmanship of their dedicated workforce, and their sincere desire to partner with their customers and suppliers. Contact Details Oliver Inc. Doug Doroh +1 631-234-1400 ddoroh@oliverinc.com Company Website https://www.oliverinc.com/

January 19, 2023 09:20 AM Eastern Standard Time

Article thumbnail News Release

Acurx Is Vying for Standard of Care in Treating Primary and Recurrent C. diff

Acurx Pharmaceuticals Inc

By Faith Ashmore, Benzinga C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United States and it causes approximately 55 deaths a day. In the elderly population, 1 in 11 individuals over the age of 65 die within the month after being infected. The infection has a high recurrent rate, about 1 in 6 patients who get C. diff will get it again within 2-8 weeks. The current treatment for C. diff is vancomycin, an antibiotic that is typically prescribed for serious pathogenic infections. While the drug is safe and has proven successful, the antibiotic has been on the market for 65 years and its effectiveness has been steadily declining as more and more bacteria have become resistant to it, consistent with the path of virtually all other antibiotics over time. Understanding the need for a new antibiotic to treat C. diff, Acurx Pharmaceuticals ( Nasdaq: ACXP ) is developing ibezapolstat, a novel first-in-class antibiotic currently in mid-stage clinical testing. It has been given Fast Track designation by the FDA and has been designated by the FDA as a Qualified Infectious Disease Product (QIDP), which grants priority review by the FDA and provides an additional five years of market exclusivity upon approval. The CDC acknowledges an ”urgent need” for new antibiotics to treat C. diff. During the Phase 2a clinical trial, 100% of the first 10 patients were clinically cured of C. diff and did not have a recurrent infection within a 28-day period after the end of treatment with no safety concerns. Because of these strong results, the Scientific Advisory Board recommended that the trial be stopped early for success. The current standard of care, vancomycin, has an average clinical cure rate of 80% with a 30% chance of recurrent infection. In comparison, ibezapolstat would be a far more suitable drug with a higher success rate if current data holds in late-stage development. Acurx is expecting similarly strong results for their Phase 2b clinical trial. The company is expected to release topline results by mid-2023 if the FDA agrees with the company’s plan for an interim analysis. If the trials continue to be a success and ibezapolstat demonstrates statistical noninferiority compared to vancomycin in curing primary C. diff, it could win FDA approval and be used as first line therapy. But of equal, or even greater, importance are the results being shown in preventing recurrence -- the major cause of C. diff morbidity and mortality, and the principal contributor to C. diff’s $4.5 billion annual cost to the US healthcare system. Being able to reduce or eliminate recurrence would be a game-changing development in treating an infection that affects so many individuals, especially amid rising bacterial resistance to vancomycin. Ibezapolstat’s potential game-changing status would be further assured if it scores well in two exploratory endpoints in the current Phase 2b trial – the number of disease-free patients at days 60 and 90 (two time points not included on any product labeled for C. diff.) and if it continues to demonstrate restoration of the healthy microbiome of C. diff patients during the treatment process. Click here for more information about Acurx. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing an entirely new class of antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Photo by Mark Fletcher-Brown on Unsplash Contact Details Acurx Pharmaceuticals, Inc. David P. Luci, President & CEO +1 917-533-1469 davidluci@acurxpharma.com Company Website https://www.acurxpharma.com/

January 19, 2023 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023

VistaGen

By Rachael Green, Benzinga In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ: VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major Depressive Disorder (MDD). The trial, involving the Company’s newly optimized formulation of PH10, is intended to confirm the favorable safety profile of PH10 established in three previous clinical studies conducted in Mexico, including a published Phase 2A study for the treatment of MDD. After receiving a “study may proceed” letter from the U.S. Food and Drug Administration (FDA) last November followed by a Fast-Track designation from the FDA in December, the late clinical-stage biopharmaceutical company is ready to start the Phase 1 trial in the first quarter of 2023. Upcoming Phase 1 Clinical Trial Will Prepare Vistagen’s Drug Candidate PH10 for Phase 2B Research On November 30, Vistagen announced that it had received a “study may proceed” letter from the FDA for PH10 as a treatment for MDD. The following week, the FDA granted Fast-Track designation to the pherine-based nasal spray. The FDA’s fast track program, meant to bring promising new treatments for serious conditions to patients sooner, makes Vistagen’s drug eligible for more frequent meetings and communications with the FDA – which can help ensure a smoother development and review process and, potentially, an earlier drug approval date. The FDA’s decision to grant Fast-Track designation was based on Vistagen’s previous preclinical and clinical research on PH10. In an earlier Phase 2A study of PH10, for example, the MDD treatment was found to significantly reduce depressive symptoms in participants after only one week of treatment and at the eight-week study endpoint. The upcoming Phase 1 study will enroll 12 participants in a double-blind, placebo-controlled clinical trial with topline data expected by the end of the first quarter. The goal of the study is to confirm the favorable safety data demonstrated in earlier clinical trials and lay the groundwork for a Phase 2B study of PH10 in MDD. On December 21, Vistagen announced its acquisition of Pherin Pharmaceuticals, a clinical-stage company developing a pipeline of pherine drug candidates. The acquisition will give Vistagen full ownership of the intellectual property rights for both PH10 and its Phase 3 pherine drug candidate, PH94B, allowing the company to stop paying royalties and milestone payments for the compounds. The deal will also add three new pherine drug candidates to Vistagen’s pipeline. PH10 Is Designed To Be A Fast-Acting Antidepressant With Minimal Side Effects In the past few years, research activity in the MDD space has picked up significantly as companies explore several new treatment options with different mechanisms of action. That’s because the currently approved antidepressants aren’t working for millions of people, leaving a massive unmet need that drug developers are racing to fill. “Nearly two-thirds of diagnosed and treated depression patients do not achieve remission with first-line therapy. With 21 million adults in the U.S. suffering at least one major depressive episode in the past year, potentially millions of individuals are not getting the help they need,” said Vistagen CEO Shawn Singh in a statement about the upcoming Phase 1 trial for the MDD treatment. While some exciting progress has been made, Vistagen hopes its drug candidate, PH10, can address some of the shortcomings of the latest alternatives to hit the market. PH10 is one of two pherine nasal sprays currently in development at Vistagen. Pherines are a new class of synthetic chemosensory messenger drug candidates that may be able to provide fast-acting relief for depression and anxiety symptoms and several other unmet medical needs. For the treatment of depression, PH10 is designed to activate chemosensory neurons in the nose that can then activate the limbic system, the areas of the brain involved in emotional response. Researchers hypothesize that it does this possibly by triggering the release of more dopamine, serotonin, and norepinephrine, three hormones that play a role in mood and happiness. This mechanism of action sets it apart from other drugs in development for depression. COMPASS Pathways, PLC (NASDAQ: CMPS), for example, is working on COMP 360 – a psilocybin-based therapy for treatment-resistant depression – which has shown promise in recent clinical trials. In one Phase 2b study, a single high dose of the psilocybin compound was able to provide immediate symptom improvement with results lasting up to 12 weeks. However, being a psychedelic, the treatment requires psychological support from a specialty-trained therapist during a psilocybin therapy session. While it may be helpful in the long run, the time-consuming process isn’t as convenient as a standalone medication that could be taken daily or as needed without interrupting the rest of the day. Meanwhile, Relmada Therapeutics, Inc. (NASDAQ: RLMD) is developing REL-1017, a compound that works by blocking the N-Methyl-D-aspartate (NMDA) receptor in the brain. The daily oral treatment is meant to work similarly to ketamine-derived treatments like Johnson & Johnson’s (NYSE: JNJ) recently approved Spravato, but without the psychotropic effects. However, the late-stage biotech announced top-line results from its Phase 3 trial of the drug candidate last October, noting that it failed to achieve its primary endpoint of significantly reducing depression symptoms compared to a placebo. PH10, on the other hand, does not require the same systemic uptake to produce its fast-acting effects, according to Vistagen. The compound doesn’t cause the same psychotropic side effects as ketamine-based treatments but has still managed to demonstrate rapid-onset and significant lasting results in the clinical studies completed so far. As trials progress, it could be worth keeping on the company as it leverages its recent wins to bring its drug to market quickly for the millions suffering from depression. This article was originally published on Benzinga here. Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are investigational neuroactive steroid nasal sprays designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details Mark Flather- Investor Relations mflather@vistagen.com Company Website https://www.vistagen.com/

January 19, 2023 08:30 AM Eastern Standard Time

1 ... 146147148149150 ... 282